Arvinas Inc.

At Arvinas, we’re leading the creation of an entirely new way to treat disease through therapies that target and degrade disease-related proteins. We are a clinical-stage biopharmaceutical company focused on developing new therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTAC® protein degraders, or proteolysis-targeting chimeras, work by harnessing the body’s own natural protein disposal system to degrade and remove disease-causing proteins.

Our leading programs are focused on high-value targets in cancer, including the androgen and estrogen receptors associated with prostate and breast cancers, respectively. Our hope is to unlock the full potential of PROTAC protein degradation by developing our own robust pipeline and by partnering with the world’s leading drug development companies.

QUALITY BENEFITS
Designed with health and wellness in mind, employees and their families are eligible for:

  • Medical, dental, and vision options, including a generous company contribution into an HSA
  • Paid maternity and paternity leave
  • FSA, HSA, Healthcare, and Dependent Care accounts
  • Company provided life insurance and short/long-term disability coverage
  • Additional voluntary benefits including critical illness, hospital care and more

COMPENSATION & EQUITY
Central to our organization is attracting, retaining and engaging the best and brightest by sharing in the success of our organization:

  • Competitive salaries and an annual incentive program
  • 401K matching program with immediate vesting
  • Eligibility for long-term equity incentives upon hire and annually

TIME OFF
We believe it’s important to relax, unwind and enjoy life’s moments:

  • Paid vacation
  • A year-end office closure
  • Observed company holidays
  • Paid sabbatical upon 5 years’ tenure

We’re really excited about the work we’re doing inside and outside of Arvinas, and think you will be, too. We take our work very seriously, but we also ensure we’re having fun while doing it. We embrace the freedom to pursue innovation, think creatively, and give back. We care about each other, celebrate our accomplishments, and rise up to encourage our colleagues through challenges. If you think one of these open positions might be a fit, we’d love to hear from you.

  • NextGen Class of 2015
5 Science Park 395 Winchester Ave
New Haven, CT 06511
  • Featured Employer
NEWS
Arvinas, Inc., a biotechnology company creating a new class of drugs based on targeted protein degradation, announced the appointment of Ronald Peck, M.D. to the newly created position of Chief Medical Officer.
Pharma, biotech and life science companies strengthen leadership teams, with news from Vertex, Arvinas, Provention, Enterome, and more.
Kymera Therapeutics secured $65 million in a Series B funding round that was supported, in part, by the investment arms of Pfizer and Sanofi.
Emeryville, Calif.-based Gritstone Oncology hits the ground running today on the Nasdaq Exchange after raising $100 million in an initial public offering.
According to BioPharm Catalyst there were, or soon will be, 58 biopharma IPOs in 2018. And the trend doesn’t appear to be slowing. Here’s a look at five upcoming biotech IPOs.
New Haven, Connecticut-based Arvinas, only a few months since raising $55 million in a Series C financing, filed for an initial public offering (IPO). The company hopes to raise $100 million.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
Pfizer will use Arvinas’ proprietary PROTAC Platform to create small molecule therapeutics aimed at degrading disease-causing cellular proteins.
JOBS
IN THE PRESS